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monitoring. In reality however, a signiﬁcant number of healthcare
providers (HCPs) do not have good HIV care experiences while
having serious service workload, prescribing ARVs without proper
laboratory monitoring may lead to more proportion of patients
with virological failure and HIV drug resistance. For RLS, it is
therefore important to implement some proper and cost-effective
monitoring strategies while operating earlier ART policy.
Inprinciples, goodHCP-patient relationship toensure treatment
adherence is “the must do” and the most cost-effective measure.
Each RLS should consider a minimal set of laboratory tests to be
included in their services such as CBC, creatinine (before initiating
TDF) for safety; TB screening and VDRL for co-infection screening.
In case of ART efﬁcacy, CD4 at baseline then 2 times a year until
CD4>350; and as long as VL is well suppressed, we may not need
further testing. WHO 2013 has recommended to perform VL test, if
available it should be tested every 6 months until becoming unde-
tectable then once a-year. There are more low cost (<3 USD/test)
and point-of-care (POC) CD4 tests available commercially. Low cost
POC VL-test is not yet available. Current low cost VL test in some
RLS is based on a homebrew real-time PCR assay (cost < 5USD/test).
However, it requires expensive equipments and experience tech-
nicians to run the service. While POC VL tests in not yet available,
HIV care system in RLS may consider setting up few central labs
to provide low cost homebrew VL test and validate the dried-
blood spot sample testing systems. Nonetheless, in settings where
resources are truly constraint, it should not prevent from imple-
menting ART for HIV symptomatic patients or thosewith CD4<350
if someessential labmonitoring isnot available.Allmeans toensure
adherence is warranted.
http://dx.doi.org/10.1016/j.ijid.2014.03.477
Type: Invited Presentation
Final Abstract Number: 13.003
Session: HIV - Antiretroviral Therapy
Date: Thursday, April 3, 2014
Time: 15:45-17:45
Room: Room 2.60
Timing of antiretroviral therapy in relation to
co-morbidities
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Antiretroviral therapy (ART) for HIV infection decreases HIV
RNA levels, increases CD4 cell counts and general immune func-
tion, prevents clinical progression, and prolongs survival. Despite
these clear beneﬁts, the optimal time of initiation of ART remains
uncertain. ART treatment guidelines worldwide agree in the rec-
ommendation to start ART in anyHIV-infected patientwith AIDS or
symptomatic HIV disease. Despite concerns about drug toxicities,
drug interactions, and the immune reconstitution syndrome, start-
ing ART earlier during an acute opportunistic infection (including
tuberculosis) clearlywasassociatedwithclinical beneﬁts, including
prolonged survival, in randomized clinical studies.More controver-
sial is the timing of starting ART during an acute central nervous
system opportunistic infection such as cryptococcosis or tuber-
culosis with some randomized clinical studies suggesting earlier
ART was associated with increased mortality. ART guidelines dif-
fer in their recommendations for starting ART in asymptomatic
patients. Some guidelines base their recommendations for start-
ing ART on speciﬁc CD4 cell count thresholds and/or the presence
of any of a number of co-morbidities such as hepatitis B, hep-
atitis C, non-AIDS malignancies requiring treatment, idiopathic
thrombocytopenic purpura (ITP), increased cardiovascular risk,
neurocognitive changes, renal disease including HIV-associated
nephropathy (HIVAN), and active or latent tuberculosis. Despite
the disagreement in treatment guidelines about the optimal time
to start ART in asymptomatic patients, there is a clear trend for
starting ART earlier in HIV infection. For example, World Health
Organization (WHO) treatment guidelines have increased CD4
cell count thresholds for starting ART from 200/uL to 350/uL
to 500/uL in recent years. Part of the rationale for starting ART
earlier is to avoid non-AIDS comorbidities that may be associ-
ated with the inﬂammation and immune activation associated
with untreated HIV infection, including cardiovascular, renal,
liver, neurologic, andmalignant diseases. Additional observational,
interventional, and randomized clinical studies are in progress
and will help inform the important decision of when to start
ART.
http://dx.doi.org/10.1016/j.ijid.2014.03.478
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The number of people living with HIV accessing antiretroviral
treatment in resource-limited countries has increased from a few
thousands pre-2000 to almost 10million in 2013. This achievement
is unprecedented in the history of public health and has resulted in
important decreases in HIV-related mortality, including a 10 year
increase in life expectancy in South Africa. Yet, this scale up is not
without problems. Retention in care is poor, data on virological
success rates is scarce, signiﬁcant numbers of patients are seek-
ing health carewith advanced immunosuppression, and increasing
medicine stock outs are symptomatic of the limits of existinghealth
systems. According to the latest WHO guidelines, another 16 mil-
lion people are in need of ART,most ofwhomdonot know their HIV
status. This presentation examines the factors contributing to the
success of the ART scale up, the challenges it faces, and strategies
to scale up further whilst maintaining quality of care.
This presentation examines the factors contributing to the suc-
cess of the ART scale up, the challenges it faces, and strategies to
scale up further whilst maintaining quality of care.
A number of critical historical factors have made this success
possible: strong activist movements in rich and poor countries,
massive increases in vertical funding, the Doha declaration on
TRIPS agreement and public health, generic competition resulting
in prices of ﬁrst line ART decrease from over 10,000 USD to less
than 100 USD per patient per year, programmatic innovations and
paradigm shifts in public health and political will. Yet the success
is unequally distributed and access to ART remains low in many
countries (such as most of central and west Africa) and popula-
tions (e.g. intravenous drug users). Challenges include losses along
the test to treatment cascade, treatment failure, pediatric and ado-
lescentHIV,medicine stock outs, overburdenedhealth systems and
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an increasing funding shortfall. Novel strategies include commu-
nity models of care, for testing, adherence support and delivery of
ART.
AIDS is far from over as challenges ahead dwarf the impressive
achievements of ART scale up to date. Yet treatment as prevention
is already showing early signs of success...
http://dx.doi.org/10.1016/j.ijid.2014.03.479
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Background: Pregnant women and young infants are at
increased risk for severe inﬂuenza-illness. Inﬂuenza vaccination
duringpregnancymay confer indirect protection against inﬂuenza-
illness to infants <6 months of age, for whom there is no licensed
inﬂuenza vaccine. A co-primary objective of our study was to eval-
uate the efﬁcacy of trivalent inactivated inﬂuenza vaccine (IIV3)
when given during pregnancy against PCR-conﬁrmed inﬂuenza-
illness (PCI) in their infants up until 6 months of age.
Methods & Materials: We conducted a double-blind, random-
ized, placebo-controlled trial in Soweto, South Africa during the
2011 and 2012 inﬂuenza seasons. 2116 HIV-uninfected women
were randomized to receive IIV3 or placebo intramuscularly
between 20-36 weeks gestation. Infants were screened weekly
for inﬂuenza-like-illness (ILI) after birth. When ILI was suspected
nasopharyngeal aspirates were collected for inﬂuenza A and B
testing by real-time PCR. Inﬂuenza A viruses were subtyped for
A/H1N1pdm09 and H3N2 and inﬂuenza B isolates were tested for
Yamagata and Victoria lineages.
Results:Pregnancyoutcomeswere similar between the IIV3and
placebo-group, including 8 miscarriages and 22 stillbirths. 2048
babies were born alive, 1025 and 1023 to mothers who received
IIV3 andplacebo, respectively. The rates of pretermdeliveries (10%)
and low birth weight (12.4%) were also similar between the study
groups. 706 and 698 illness visits were completed in infants of
mothers who received IIV3 and placebo, respectively; of which
665 (64.9%) and 656 (64.1%) illness episodes fulﬁlled ILI crite-
ria. In infants born to IIV3-recipients, 19 PCI cases were detected
compared to 37 in infants born to placebo-recipients, resulting
in vaccine efﬁcacy of 48.8% (95%CI: 11.5% to 70.3%) against PCI
in infants. Excluding the non-vaccine inﬂuenza B/Yamagata cases
from the analysis vaccine efﬁcacy (VE) did not change (VE: 48.1%;
95%CI: -0.9% to 73.3%). In twelve (21.4%) of the 56 PCI cases among
infants (including 11 whose mothers received placebo), PCI was
also identiﬁed concurrently in the mother.
Conclusion: Vaccination of African pregnant women with IIV3
was safe and reduced PCI in their infants by 49% up until 6 months
of age. Immunization of pregnant women with IIV3 is warranted
for the protection of their young infants.
http://dx.doi.org/10.1016/j.ijid.2014.03.480
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Background: Acute respiratory infections (ARIs) are a major
cause ofmorbidity andmortality among childrenworldwide. How-
ever, information about viral etiologies ofARIs fromdeveloping and
tropical countries is limited. Understanding the etiologies of ARIs
in hospitalized children is essential for improving prevention, diag-
nosis and treatment in these settings. This study was conducted to
describe the clinical and epidemiologic characteristics of viral ARIs
in hospitalized children in Vietnam.
Methods & Materials: From April 2010 to May 2011, clinical
data and nasopharyngeal (NP) samples were collected from chil-
dren with ARIs admitted to Children’s Hospital 2 at Ho Chi Minh
City, Vietnam. Four multiplex PCR assays were performed to detect
13 respiratory viruses in NP samples.
Results: A total of 1,082 were enrolled. At least one pathogen
wasdetected in 64%of caseswith 9.1%were co-infections. Themost
frequent pathogens were rhinovirus (RV) (30%), respiratory syncy-
tial virus (RSV) (23.8%), human bocavirus (HBoV) (7.2%) followed
by parainﬂuenzae virus (PIV) type 3 (5.3%), PIV type 1 (3.3%), and
inﬂuenzaA (FluA) (3.2%). RV infectionoccurredall year round,while
RSV epidemic occurred mainly in the rainy season. FluA infections
peaked in both seasonswith seasonal H3N2 in the rainy season and
pandemic H1N1 2009 in the dry season. Other viruses were pre-
dominant in thedry season.RV infectionsoccurred inall agegroups.
RSV, PIV3, PIV1 and HBoV, FluA caused infections predominantly
in children<6 months, 6 – 12 months, 12 – 24 months, and>24
months, respectively. Signiﬁcant associations were found between
PIV1 with croup (p<0.005) and RSV with bronchiolitis (p <0.005).
HBoVandRV infectionswere associatedwithhypoxia (p <0.05) and
RSV infectionswith lower chest indrawing (p<0.05). RSV subgroup
A had severity score higher than subgroup B (p<0.05). Pandemic
H1N1 2009 and co-infections did not lead to more severe symp-
toms.
Conclusion: A high incidence of virus-associated ARIs, in which
RV, RSV and HBoV were the leading causes, was found among hos-
